|
|
Coreg
The intensively treated group had fasting blood sugars reduced to 108even tighter control than the american diabetes association's goal of 12 tight control of blood sugars resulted in a 33% reduction in kidney disease, 16% reduction in heart attacks, and a 21% reduction in diabetic retinopathy.
4WD vehicle Toyota Land Cruiser Model 2003. Photo attached ; Bilingual Spanish-English driver. 1 person ; 28.000Km Fully insured for the car & 11 passengers ; . Clear glass windows. Roof-rack for the luggage and cover. Ice box for drinks. First Aid Kit. Permit to travel with tourist around Venezuela. Expenses for the lodging & meals for the guide driver for the whole trip. Expenses for the petrol for the whole tour. Parking cost for the vehicle.
Are in accordance with the special needs of the residents; and ii ; Will not adversely affect residents' health and safety. Interpretive Guidelines 483.70 d ; 3 ; A variation must be in accordance with the special needs of the residents and must not adversely affect the health or safety of residents. Facility hardship is not part of the basis for granting a variation. Since the special needs of residents may change periodically, or different residents may be transferred into a room that has been granted a variation, variations must be reviewed and considered for renewal whenever the facility is certified. If the needs of the residents within the room have not changed since the last annual inspection, the variance should continue if the facility so desires. Interpretive Guidelines 483.70 d ; 1 ; i ; residents are transferred or discharged from rooms with more than four residents, beds should be removed from the variance until the number of residents occupying the room does not exceed four.
I. Carvedilol Coregg ; 1. FDA approval for NYHA II &III `97 ; 2. 1 & -blockers : ; effects of SAS 3. Initial ; TPR, VR 4. Subsequent ; HR, ; SV 5. Antiarrhythmic Action 6. Slows Progression of CHF; 7. ; Mortality ??? Dr. Tenner skipped this slide.
Like codeine ; -and-if so-what do you use for pain now.
Recommendation: Dismiss Dr. Robert Mitchell motioned to accept counsel's recommendation and then withdrew his motion due to the expired drug issue. After board discussion, Dr. Robert Mitchell motioned to dismiss the complaint; seconded by Dr. Sheila Mitchell. All were in favor and the motion carried. 20. Case No.: L06-PHR-RBS-200602388 Complainant alleges that her husband's prescription for Doreg Tab 6.25mg was mistakenly filled with Cogeg Tab 25mg. Complainant's husband detected the error before any of the incorrect medication was consumed. Complainant and husband went back to the pharmacy the next day to get the prescription filled correctly. Respondent admits that the misfill occurred. When the error was brought to the PIC's attention, it was reported to the risk management department. The patient was also given the correct medication and refunded the cost of the medication. Prior complaints: PIC & Pharmacy: 20050440 5 2005-Dismissed Recommendation: Letter of Warning Dr. Reggie Dilliard motioned to accept counsel's recommendation; seconded by Dr. Bettie Wilson. All were in favor and the motion carried. 23. Case No.: L06-PHR-RBS-200603287 Complainant states that she stopped by the pharmacy to obtain information only about a prescription for Sanctura 20mg. Complainant did not ask to have the prescription filled, but wanted to know if it came in a generic Oxybutynin ; and asked the price. Complainant states that the pharmacist told her that it did and gave her a price and did tell the Complainant that she would have to bring in a new prescription. Pharmacist states that she did speak with the Complainant and looked up the medication in the AARP formulary and told her how much the medication would cost. Pharmacist denies telling Complainant that Oxybutinin is the generic for Sanctura. Prior complaints: 199901745 - Closed Recommendation: Dismiss Mrs. Monica Franklin motioned to accept counsel's recommendation; seconded by Dr. Bettie Wilson. All were in favor and the motion carried. 24. Case No.: L06-PHR-RBS-200603282 and cozaar.
Metabolic Worldwide sales for the metabolic category were 1.1 billion, up 20 per cent. The Avandia franchise Avandia and Avandamet ; grew 24 per cent for the year with US sales up 20 per cent to 755 million. Avandamet, a combination of Avandia and metformin HCI, expanded the Avandia metabolic franchise with its US launch in the fourth quarter 2002. In Europe, Avandia has benefited from increasing physician acceptance with sales of 70 million, up 57 per cent. The franchise should benefit further from the EU approval of Avandamet in December 2003. Avandia also did very well in International markets with sales of 106 million, up 40 per cent. Vaccines Sales of vaccines grew two per cent to 1.1 billion, supported by the Infanrix Pediarix franchise, up 32 per cent to 336 million. The hepatitis franchise declined 13 per cent to 417 million reflecting competitive pressure in the USA and Europe. In the USA, GlaxoSmithKline's new Pediarix vaccine was launched in January 2003. Pediarix adds protection against hepatitis B and poliomyelitis to the Infanrix combination and results in up to six fewer injections for infants. Cardiovascular and urogenital In 2003, Cogeg sales grew 28 per cent to 361 million, benefiting from recent data that showed a highly significant statistical difference in survival between Ckreg and metoprolol in patients with heart failure. Levitra vardenafil ; , a new agent for the treatment of erectile dysfunction, was launched in the USA in August 2003 and in Europe in the first half of the year. Levitra was researched and developed by Bayer AG and is co-promoted with GlaxoSmithKline. Oncology and emesis Sales of Zofran grew 16 per cent to 774 million, driven by a strong US performance, up 20 per cent to 575 million. Other therapeutic areas Sales of Zantac fell 13 per cent to 328 million with declines in all regions.
Study did not answer the question of whether treatment of depression can decrease or negate this association. Depression during the postmyocardial infarction period has a significant negative impact on functional status and the ability to adhere to cardiac rehabilitation plans. The presence of depressive symptoms following an ischemic event has been correlated with a decreased effect on the maintenance of healthy behavior changes during and after the rehabilitation period smoking cessation exercise class lifestyle changes ; .1215 Studies have found that depressed patients were 40% less likely to stop smoking, more likely to quit exercise programs, and experienced greater stress and social difficulties after a myocardial infarction.1214 In a study by Steffens et al., 335 hospitalized patients with CAD were interviewed with regard to functional capacity.15 This process included evaluation of the patient's ability to perform activities of daily living basic selfmaintenance tasks ; as well as instrumental activities of daily living such as preparing meals, doing yard work, managing finances, etc. ; . The presence of depression in patients with CAD was associated with significant deficits in the ability to complete activities of daily living and instrumental activities of daily living resulting in increased functional impairment as compared with a nondepressed control group. Although one cannot assign a direct causal relationship from this trial alone, this degree of functional impairment should be of great concern to all health care providers and crestor.
Coreg side
At a Capitol Hill briefing, The Honorable Billy Tauzin, president and CEO, Pharmaceutical Research and Manufacturers of America, joined Mary Woolley, president and CEO, The Honorable Billy Tauzin; Tian-Li-Yue; Eliot Ohlstein, PhD; Robert Ruffolo Jr., PhD; Mary Woolley Research!America; Alan Metz, MD, vice president and medical director, GlaxoSmithKline; and several members of Congress to honor the scientists and researchers who discovered and developed GlaxoSmithKline's cardiovascular medicine Coreg. Coreg has reduced mortality from congestive heart failure and has changed the paradigm for treating this disease. It is used by patients to treat high blood pressure and prevent recurrent heart attacks. "The recipients of these awards . played such an incredible role in advancing health care here in America and around the world, " Tauzin said. "Millions of patients will now live healthier, longer lives because of their work." Media coverage of the event included the Philadelphia Business Journal online, Forbes and Reuters.
Therapeutic drug class beta blockers oral ; effective 4 2 07 preferred agents acebutolol atenolol betaxolol bisoprolol inderal la propranolol ; metoprolol nadolol pindolol propranolol sotalol timolol toprol xl metoprolol ; carvedilol coreg carvedilol ; labetalol ditropan xl oxybutynin ; enablex darifenacin ; oxybutynin oxybutynin er oxytrol oxybutynin ; sanctura trospium ; vesicare solifenacin ; non-preferred agents beta blockers betapace sotalol ; blocadren timolol ; cartrol carteolol ; corgard nadolol ; innopran xl propranolol ; kerlone betaxolol ; levatol penbutolol ; lopressor metoprolol ; sectral acebutolol ; tenormin atenolol ; zebeta bisoprolol ; beta- and alpha- blockers nr coreg cr carvedilol ; trandate labetalol ; detrol tolterodine ; detrol la tolterodine ; ditropan oxybutynin ; all of the preferred agents in the class must be tried before a nonpreferred agent will be authorized unless one of the exceptions on the pa form is present and diovan.
Faculty of Chemistry, University of Gdask, Sobieskiego 18, 80-952 Gdask, Poland Institute of Biotechnology, University of Texas Health Science Center, 15355 Lambda Dr, 78245 San Antonio, Texas, USA; elaj chem v.gda.
Coreg tablets
| Coreg side effectsVaccines The vaccines business had a strong year, with sales up 11% to 1.2 billion. Several key products drove growth Pediarix Infanrix up 12% to 356 million, Priorix, up 14% to 95 million and Fluarix, up 38% to 79 million. Oncology and emesis Sales of Zofran grew 8% to 763 million, driven by the US performance, up 10% to 565 million. Cardiovascular and urogenital In 2004, Coreg for heart disease ; sales grew 34% to 432 million. Other therapeutic areas Sales of Zantac fell 12% to 273 million, with declines in all regions. USA The USA reported flat turnover in 2004 despite the significant impact of generic competition to Paxil and Wellbutrin. Excluding sales of these products, turnover grew 10%. The US business represented 49% of total pharmaceutical turnover in 2004 and hytrin.
A ACCU-CHEK STRIPS AND KITS ACTONEL ACTONEL WITH CALCIUM ACTOPLUS MET ACTOS acyclovir ADVAIR ADVICOR albuterol ALLEGRA-D 4 ALPHAGAN P ALTACE amlodipine amoxicillin amoxicillin-clavulanate ANDROGEL APIDRA ASMANEX ASTELIN ATACAND 2 ATACAND HCT atenolol AVALIDE AVAPRO AVELOX azithromycin B BD INSULIN SYRINGES AND NEEDLES BENICAR BENICAR HCT BENZACLIN BETIMOL BETOPTIC S brimonidine 0.2% bupropion bupropion ext-rel BYETTA C CADUET carvedilol cefaclor cefdinir cephalexin cholestyramine CIPRO SUSPENSION ciprofloxacin ext-rel ciprofloxacin tablet citalopram clarithromycin clarithromycin ext-rel CLIMARA COMBIVENT COPAXONE COREG CR COUMADIN CYMBALTA D DETROL DETROL LA dicloxacillin DIFFERIN digoxin diltiazem ext-rel doxazosin doxycycline hyclate DUAC DUETACT E EFFEXOR XR ENABLEX ENJUVIA EPIPEN EPIPEN JR erythromycinbenzoyl peroxide erythromycins ESTRADERM estradiol estropipate ethinyl estradiollevonorgestrel EVISTA.
Phase V Therapeutic Classes New Clinical Information Review Dr. Baker provided the Board with clinical updates to Phase V Supplemental Rebate drugs listed in the Supplemental Rebate section of the DURB binder. The following drugs had updates: Therapeutic Class Beta Blockers Coreg Toprol XL Beta Blocker-Diuretic Combos Timolide Serotonin Receptor Agonists Imitrex New Generation Antidepressants Cymbalta Effexor Effexor XR Wellbutrin XL Thiazolidinediones TZDs ; Actos Avandia Non-Insulin Antidiabetic Agents Avandamet Byetta Tumor Necrosis Factor TNF ; Inhibitors Humira Low Sedating Antihistamines and Combination Products Clarinex Trinalin Zyrtec Sedative Hypnotics Ambien, CR Lunesta Rozerem Sonata Zolpidem generic Dr. Williams commented on two other studies done on Avandia and Actos and commented on Rozerem's effect on hormones. Drugs and innopran.
|
The coreg product can contain up to four image cubes: 1. the VNIR cube with high-resolution nominally 5m ; sampling of bands ABCD; 2. the IR cube with low-resolution nominally 20m ; sampling of bands EFGHIJKLMNO; 3. a VNIR cube with the same low-resolution as the IR cube this has no new information, but makes the simultaneous exploitation of the visible and infrared bands more convenient and 4. a top-of-atmosphere brightness temperature cube involving only the thermal IR bands JKLMN. Not all bands are active for all images, and if for instance bands ABCD are not active as is often the case for a nighttime collect ; , then the VNIR cubes will not be provided. Quality images are provided for whichever of the data cubes are available except we do not produce a quality image for the brightness temperature cube since that information is in the IR quality cube ; . In addition to the data and quality images, the coreg product provides a wealth of auxiliary information about the overflight, and about the coregistration process. Table 2 provides a list of some of these variables and arrays. This information is also available in the header file that comes with the coreg product.
CELEBREX.6 CELEXA.8 CELLCEPT.17 CENESTIN .16 cephalexin .7 chlorthalidone .12 chlorzoxazone .19 cholestyramine .12 cholestyramine light.12 CIALIS.16 cilostazol .11 cimetidine.15 CIPRO XR .7 ciprofloxacin HCL .7 citalopram HBR .8 CLARINEX .18 clidinium chlordiazepoxide.15 CLIMARA .16 clindamycin HCL .7 clobetasol propionate.15 clonidine HCL.12 clotrimazole.15 clotrimazole betamethasone .15 colchicine .8 COLYTE WITH FLAVOR PACKETS .15 COMBIVENT.18 COMTAN.9 COREG .12 COUMADIN.11 COZAAR .12 CRESTOR.12 cyclobenzaprine HCL .19 CYMBALTA .8 cyproheptadine HCL .15 DEPAKOTE .7 DEPAKOTE ER.7, 9 desonide .15 desoximetasone .15 DETROL.16 DETROL LA .16 dexamethasone.6, 18 diclofenac sodium .6 dicyclomine HCL .15 digitek.12 digoxin.12 DILANTIN .7 diltia XT .12 diltiazem HCL ER .12 and atacand.
Coreg hydrochloride
Jon's 1-26 reply to joe s' 1-26 possibilities shirley 1-26 to maxine about pacemaker info stephanie's 1-26 reply to joe s' 1-26 possibilities jon 1-26 page updates mary 1-28 problems using hands & sitting - questions amelia 1-28 update, broke my foot ralph's 1-28 reply to sharon's 1-21 coreg problems jon's 1-28 reply to ralph's 1-28 some points to ponder nikos k 1-28 some chf questions & about this site jon's 1-28 reply to nikos k's 1-28 about this site's sponsorship status mary lou's 1-29 reply to autumn's 1-21 peripheral neuropathy experience sabrina 1-29 does anyone have trouble sleeping.
Posted in uncategorized no comments » resolved question: have you noticed how many questions are asked about hepatitis c and lopid.
Drug Name COLBENEMID COLESTID COLYTE COMBIPATCH COMBIVENT COMBIVIR COMPAZINE COMTAN CONCERTA CONDYLOX CONTRACEPTIVE HORMONES CORDARONE COREG CORTEF CORTENEMA CORTISPORIN OTIC susp, soln COSOPT COUMADIN COZAAR CREON CRESTOR Generic Name Probenecid Colchicine Colestipol Hcl Polyethylene Glycol Estradiol Norethindrone Patch Albuterol Sulfate Ipratropium MDI Zidovudine Lamivudine Prochlorperazine Entacapone Methylphenidate Hcl Podofilox Topical ; All Forms Amiodarone MC * F NF for CCS screening PA ; for CCS screening F F F for CCS screening F Limit of 10 mls month. Limit of 2 units month. MC * Bill State Medi-Cal.
Experimental toxicologic studies on 8-methoxypsoralen mals exposed to the long ultraviolet. R. E. Hakim, Freeman, A. C. Griffin, J. M. Knox. Quantitative the rat: phenelzine Steinetz. measurement of Evans blue influence of 5-hydroxytryptamine on experimental inflammation. space and lotensin.
We will make periodic updates to the ms community using various channels, including, for example, presentations at major medical meetings.
This report on a class of drugs called beta-blockers is part of a Consumers Union and Consumer Reports project to help you find safe, effective medicines that give you the most value for your health care dollar. To learn more about the project and other drugs we've evaluated, go to CRBestBuyDrugs . Beta-blockers are used by tens of millions of Americans everyday. In 2004 they were the fifth most widely prescribed class of medicine. They are used primarily to treat people with high blood pressure. But they are also used to treat other heart conditions. These include angina heart or chest pain ; , abnormal heart rhythms, coronary artery blockages, and heart failure. They are also used, along with other treatments, to help prevent repeat heart attacks in people who have already had one, to prevent migraine headaches, and to treat performance or stage-fright anxiety. Fourteen beta-blockers are currently available. All but two -- carvedilol Coreg ; and metoprolol succinate Toprol XL ; -- are now available as generic drugs. These two drugs are chemically distinct from other beta-blockers, too. Some beta-blockers are very inexpensive, costing about to a month. See Table 3 on pages 10-13 ; . Metoprolol succinate Toprol XL ; is priced competitively with generics. The 14 drugs are and lozol and Order coreg online.
Nonrandomized, crossover study of 188 patients with mild-to-severe HF or asymptomatic post-MI LVD compared COREG and COREG CR. Patients received COREG 3.125, 6.25, 12.5, or 25 mg twice daily ; for 2 weeks and then the equivalent dose of COREG CR 10, 20, 40, or 80 mg once daily ; for 2 weeks. Compliance at each visit Number dispensed Number returned ; X 100 Number of tabs or caps day ; X Number of days since last visit ; . Noncompliance subject took less than 80% or more than 120% of study medication. Packer M et al. J Cardiol. 2006; 98: 39L45L. Data on file #79 ; . GlaxoSmithKline.
We would like to thank particularly the following investigators: alzieu, aouizerate-pelletier, arnaud-jourdan, aubry, aymonin, becherel, bensadou-dahan, bequidt-massardier, berrissoul-mauriat, berthault-guguelmi, berthier, boachon, berthod, bey, bineau, boccaccio-vachette, bonneau, bonnefoy, bories, bouilly-auvray, bourdet, boursier, bouyx, bozec, brun, brunault, buffet-seriot, cabarrotmoreau, carboni, carena-damge, carlier, carmi, cartier, caspardfriederich, castel, catala, caujolle, cavana-froger, charpentier, chavigny, chemidling, christol, claye, cogrel, courtin-escandel, courtois, coutant-foulc, david, de longueau, delage-buffolo, delhalle, demain, demengeon, deschamps-pirot, desruelles, desvalles, devictor, dimov, donnadieu, drevon, dubegny, dubois, duclos, ducrot, ducrot, dupin-capeyron, durand, durande, duthoit, ehrstein, emery-delourme, esquenet, etesse-pichon, eymard, fabbrizio, favre, fermond, ficat, fleischann, foucault, fouchard, foucher, fourcade-lasnier, galissier-cabanie, gallay, gand, gavanou, garat, garreau, geindre, genolier-weiller, gervais, giraudbernhard, goldberg, grammatico, gurin, guibaud, guilda-zerbib, haas, hardy, hatchuel, hitter, houitte, huet, interligator, jacquelin, jaubert, jehannin, jelen, joganah, kleis, laglenne, laine, lang-pochon, lardy-bellenoue, lassalle, lassre, launay, laurent, le clouerec, le bozec, le coant, le monnier, le pillouer-prost, le viguelloux, leblanc-mosnier, lebre, leclercq, lefebvre-labalette, lellouche, lemonnier, lenique, lepeytre, levy-rameau, locq-ebner, logeais, loiseau-gailliard, loubeyres, loustalan, lucas-moullec, maghia, marlier-facon, mazgaj-devisse, meslier, michel, morand-touraine, moulin, mouret, mourier, massicot, neuwirth-frantisek, nicol, nory-houssin, ovtchinnikoff, par, patarin, perrollaz, pignal, petit-jacquin, pourchot, reverte, revillion, rey, ribeaudeau, rivire, roger, rogerie, romano-arnal, roquet, rostain, roux, ruer, sarda-thomas, sarrat, serrero, sirieix, solier, sourisse, steiner, tisserand, treffandier, varlet, vermynck, vicart, vidalmichel, villeneuve, weber, weiller and mevacor.
Coreg dosage
ASSOCIATION BETWEEN PREGNANCY-INDUCED HYPERTENSION AND POST-PARTUM INFECTION IN THE INSTITUTO MATERNO INFANTIL, BOGOT, COLOMBIA. CASE CONTROL STUDY.
Diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities. In heart failure patients with diabetes, carvedilol therapy may lead to worsening hyperglycemia, which responds to intensification of hypoglycemic therapy. It is recommended that blood glucose be monitored when carvedilol dosing is initiated, adjusted, or discontinued. Studies designed to examine the effects of carvedilol on glycemic control in patients with diabetes and heart failure have not been conducted. In a study designed to examine the effects of carvedilol on glycemic control in a population with mild-to-moderate hypertension and well-controlled type 2 diabetes mellitus, carvedilol had no adverse effect on glycemic control, based on HbA1c measurements [see Clinical Studies 14.4 ; ]. 5.7 Peripheral Vascular Disease -blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. Caution should be exercised in such individuals. 5.8 Deterioration of Renal Function Rarely, use of carvedilol in patients with heart failure has resulted in deterioration of renal function. Patients at risk appear to be those with low blood pressure systolic blood pressure 100 mm Hg ; , ischemic heart disease and diffuse vascular disease, and or underlying renal insufficiency. Renal function has returned to baseline when carvedilol was stopped. In patients with these risk factors it is recommended that renal function be monitored during up-titration of carvedilol and the drug discontinued or dosage reduced if worsening of renal function occurs. 5.9 Anesthesia and Major Surgery If treatment with COREG is to be continued perioperatively, particular care should be taken when anesthetic agents which depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used [see Overdosage 10 ; for information on treatment of bradycardia and hypertension]. 5.10 Thyrotoxicosis -adrenergic blockade may mask clinical signs of hyperthyroidism, such as tachycardia. Abrupt withdrawal of -blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm. 5.11 Pheochromocytoma In patients with pheochromocytoma, an -blocking agent should be initiated prior to the use of any -blocking agent. Although carvedilol has both - and -blocking pharmacologic activities, there has been no experience with its use in this condition. Therefore, caution should be taken in the administration of carvedilol to patients suspected of having pheochromocytoma. 5.12 Prinzmetal's Variant Angina Agents with non-selective -blocking activity may provoke chest pain in patients with Prinzmetal's variant angina. There has been no clinical experience with carvedilol in these patients although the -blocking activity may prevent such symptoms. However, caution should!
Generic coreg cr name: generic coreg cr fda approves first versions of gsk s cardiovascular drug carvedilol ; carvedilol phosphate ; extended-release generic coreg cr capsules.
25mg to 50mg coreg bid over 12 month's time.
Trade Name Usual Dose Range, Total mg day * Frequency per Day ; Selected Side Effects and Comments * Postural hypotension, bronchospasm Coreg 12.5-50 2 ; Normodyne, Trandate 200-1, 200 2 ; Apresoline Loniten 50-300 2 ; 5-100 1 ; Headaches, fluid retention, tachycardia Lupus syndrome ; Hirsutism ; Cardizem SR Cardizem CD, Dilacor XR, Tiazac Posicor 120-360 2 ; 120-360 1 ; Conduction defects, worsening of systolic dysfunction, gingival hyperplasia Nausea, headache ; 50-100 1 ; Isoptin SR, Calan SR Verelan, Covera HS Norvasc Plendil DynaCirc DynaCirc CR Cardene SR Procardia XL, Adalat CC Sular 90-480 2 ; 120-480 1 ; 2.5-10 1 ; 2.5-20 1 ; 5-20 2 ; 5-20 1 ; 60-90 2 ; 30-120 1 ; 20-60 1 ; No worsening of systolic dysfunction; contraindicated with terfenadine [Seldane], astemizole [Hismanal], and cisapride [Propulsid] ; Constipation ; Edema of the ankle, flushing, headache, gingival hypertrophy Common: cough; rare: angioedema, hyperkalemia, rash, loss of taste, leukopenia 5-40 1-2 ; 25-150 2-3 ; 5-40 1-2 ; 10-40 1-2 ; 5-40 1 ; 7.5-15 1-2 ; 5-80 1-2 ; 1.25-20 1-2 ; 1-4 1 ; 25-100 1-2 ; 80-320 1 ; 150-300 1 ; Angioedema very rare ; , hyperkalemia and buy cozaar.
Performance for the quarter was impacted most in the USA, where sales declined 31% to 226 million. Reported US sales growth was also impacted by comparison to a strong performance in Q2 2006 when sales grew 33% ; , which benefited from restocking of Avandia and Avandamet. For the week-ending 13th July 2007, Avandia's share of new and total retail prescriptions in the oral anti-diabetic market was 6.2% and 7.4%, respectively compared with shares of 11.5% and 11.7% respectively for the week-ending 18th May 2007. These represent decreases of approximately 46% and 37% in the volume of new and total prescriptions since the publication of the meta-analysis. Sales in Europe grew 20% to 63 million driven by growing use of Avandamet with limited impact on performance to date from the published meta-analysis. Sales in International markets declined 9% to 60 million. Lamictal, Valtrex, and Coreg combined sales grew 22% to 699 million Sales of Lamictal, for the treatment of epilepsy and bipolar disorder, grew 18% to 271 million, driven by strong sales performance in the USA, up 28% to 221 million. Sales of Valtrex, for herpes, rose 14% to 226 million, with US sales up 16% to 161 million. Sales of Coreg and Coreg CR, for heart conditions, were 202 million, up 37%. Based on the most recent retail prescription data, Coreg CR now represents over 21% of new prescriptions for the total Coreg franchise. Avodart, Requip, Boniva and Arixtra delivered combined turnover of 213 million, up 54% Sales of Requip, for Parkinson's disease and restless legs syndrome, grew 41% to 84 million in the quarter. Avodart, for benign prostatic hyperplasia enlarged prostate ; , continued to perform strongly with sales up 39% to 67 million. GSK's share of the co-promotion income for Boniva Bonviva, the only oncemonthly medicine for post-menopausal osteoporosis, was 36 million. Sales of Arixtra, a once-daily anticoagulant, doubled to 26 million. During the quarter, GSK received a positive opinion from EU regulatory authorities to extend use of Arixtra for the treatment of patients with acute coronary syndrome. In June, GSK launched Arixtra in Japan for the prevention of venous thromboembolism. Successful new NCE launches Tykerb Tyverb, Veramyst and Altabax Sales of Tykerb Tyverb, for breast cancer, were 12 million in the quarter following launch in the USA at the end of March. During the quarter, GSK gained approval of Tykerb Tyverb in Australia and Switzerland. Veramyst, a new once-daily nasal spray for the treatment of seasonal and year-round allergy symptoms in adults and children as young as two years of age, was launched in the USA in June. Altabax, for impetigo, was launched in the USA in May. In June, Altabax was approved for use in treatment of impetigo and other skin infections in Europe, where it will be known as Altargo. Other products Total sales of HIV products were 364 million, down 3%, reflecting competition to older products, Combivir -13% to 117 million ; and Epivir -21% to 40 million ; , partially offset by strong sales growth from new products Epzicom Kivexa + 43% to 79 million ; and Lexiva + 9% to 33 million ; . Sales of Relenza, GSK's anti-viral for influenza, were 67 million reflecting continuing demand from governments to stockpile it for use in the event of a flu pandemic. Sales of Zofran -76% to 55 million ; , Flixonase Flonase -15% to 55 million ; and Wellbutrin XL -40% to 117 million ; decreased as a result of generic competition to these products.
ANTIPARKINSON AGENTS Amantadine generics & Symmetrel ; Apomorphine Apokyn ; Benztropine Mesylate generics & Cogentin ; Bromocriptine generics & Parlodel ; Carbidopa Levodopa generics & Sinemet ; Carbidopa Levodopa CR generics & Sinemet CR ; Carbidopa Levodopa Entacapone Stalevo ; Entacapone Comtan ; Pramipexole Mirapex ; Ropinirole Requip ; Selegiline generics & Eldepryl ; Trihexyphenidyl generics & Artane ; ANTIVIRAL AGENTS Adefovir Hepsera ; Amantadine generics only ; Amantadine 100mg Tablets Symmetrel ; Acyclovir generics only ; Acyclovir 250mg 5ml Suspension Zovirax ; Ganciclovir generics & Cytovene ; Indinavir Crixivan ; Lamivudine Epivir HBV ; Oseltamivir Tamiflu ; Ribavirin generics & Rebetol Copegus ; Valacyclovir Valtrex ; Valganciclovir Valcyte ; All drugs indicated for the treatment of HIV & its opportunistic infections are presently on Formulary. ARTHRITIS - DISEASE MODIFYING AGENTS Anakinra Kineret ; Auranofin Ridaura ; Etanercept Enbrel ; Leflunomide generics & Arava ; Methotrexate Dose Pack generics &Rheumatrex ; Methotrexate Trexall ; Sulfasalazine generics & Azulfidine Azulfidine Entab ; CARDIOVASCULAR ANGIOTENSIN II ANTAGONISTS ARBS ; - - Losartan Cozaar ; Valsartan Diovan ; ANGIOTENSIN CONVERTING ENZYME INHIBITORS ACEIS ; Benazepril generics & Lotensin ; Captopril generics only ; Enalapril generics only ; Lisinopril generics only ; Quinapril generics & Accupril ; Ramipril Altace ; ANTICOAGULANTS ANTITHROMBOTICS - - ASA Dipyridamole ER Aggrenox ; Clopidogrel Plavix ; Enoxaparin Lovenox ; Ticlopidine generics & Ticlid ; Tinzaparin Innohep ; Warfarin generics & Coumadin ; ANTI-ADRENERGIC AGENTS - BETA BLOCKERS - - Atenolol generics & Tenormin ; Carvedilol Coreg ; Labetalol generics & Trandate Normodyne ; Metoprolol generics & Lopressor ; Metoprolol XL Toprol XL ; Pindolol generics only ; Propranolol generics & Inderal ; Propranolol LA Inderal LA ; Propranolol XL Innopran XL ; ANTI-ADRENERGIC BLOCKERS - CENTRALLY ACTING - - Clonidine generics & Catapres ; Clonidine Transdermal Catapres TTS ; Methyldopa generics & Aldomet ; ANTI-ADRENERGIC BLOCKERS - PERIPHERALLY ACTING Doxazosin generics only ; Prazosin generics & Minipress ; Tamsulosin Flomax ; Terazosin generics only ; ANTIARRHYTHMICS- - Amiodarone generics & Cordarone.
1.3.2.2. Raman spectroscopy FT-Raman spectroscopy provides molecular information about both the crystalline and the amorphous phases. It has recently been used to quantify mixtures of polymorphs, utilizing distinct spectral peaks characteristic of each form or factor analysis techniques. One advantage of FT-Raman spectroscopy is that no sample preparation is necessary, thus, the likelihood of inducing phase changes through processing is reduced. However, sample heating is a well-known problem associated with laser Raman spectroscopy, which could result in crystallization of the sample. Non-homogeneities in mixing are another source of error in quantitating the degree of crystallinity 58 ; . Results from the DSC measurements should be interpreted with caution since changes in the physical state of solid dispersions may occur during heating, and the presence of the polymer may influence the melting behavior of the drug e.g. through melting point depression. Thus the Raman results are considered to be a more reliable 31.
Where to buy Coreg
|
